Glycyrrhizic acid attenuated glycative stress in kidney of diabetic mice through enhancing glyoxalase pathway

Mol Nutr Food Res. 2014 Jul;58(7):1426-35. doi: 10.1002/mnfr.201300910. Epub 2014 Mar 3.

Abstract

Scope: Antiglycative effects of glycyrrhizic acid (GA) in kidney of diabetic mice were examined.

Methods and results: GA at 0.05, 0.1, and 0.2% was supplied to diabetic mice for 9 wk. Results showed that GA intake increased its deposit in kidney, raised plasma insulin level, decreased plasma glucose and blood urine nitrogen levels, and improved creatinine clearance rate (p < 0.05). GA intake dose-dependently reduced renal carboxymethyllysine level, and at 0.1 and 0.2% decreased plasma HbA1c, urinary glycated albumin, and renal pentosidine levels (p < 0.05). Dietary GA intake declined renal aldose reductase activity and protein expression, as well as lowered renal fructose and sorbitol levels (p < 0.05). GA intake dose-dependently increased glyoxalase-1 activity and expression, and decreased renal methylglyoxal level (p < 0.05). This compound at 0.1 and 0.2% raised glyoxalase-2 activity and protein expression, and increased d-lactate formation (p < 0.05). GA intake dose-dependently suppressed renal expression of nuclear factor kappa B (NF-κB) p65 and p-p38, decreased reactive oxygen species production, and retained glutathione content (p < 0.05). This compound at 0.1 and 0.2% downregulated renal expression of NF-κB p50 and p-ERK1/2 (p < 0.05), and lowered renal level of monocyte chemoattractant protein-1 (MCP-1) and intercellular adhesion molecule-1 (ICAM-1).

Conclusions: These findings suggest that glycyrrhizic acid is an antiglycative and renal-protective agent.

Keywords: Diabetic nephropathy; Glycation; Glycyrrhizic acid; Glyoxalase-1; Methylglyoxal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldehyde Reductase / genetics
  • Aldehyde Reductase / metabolism
  • Animals
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Diabetes Mellitus, Experimental / drug therapy*
  • Dose-Response Relationship, Drug
  • Fructose / urine
  • Glutathione / metabolism
  • Glycyrrhizic Acid / pharmacology*
  • Intercellular Adhesion Molecule-1 / genetics
  • Intercellular Adhesion Molecule-1 / metabolism
  • Kidney / drug effects*
  • Kidney / metabolism
  • L-Iditol 2-Dehydrogenase / metabolism
  • Lactoylglutathione Lyase / genetics
  • Lactoylglutathione Lyase / metabolism
  • Male
  • Mice
  • Mice, Inbred BALB C
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Oxidative Stress / drug effects*
  • Reactive Oxygen Species / metabolism
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / metabolism
  • Sorbitol / urine
  • Thiolester Hydrolases / genetics
  • Thiolester Hydrolases / metabolism

Substances

  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Icam1 protein, mouse
  • NF-kappa B
  • Reactive Oxygen Species
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Intercellular Adhesion Molecule-1
  • Fructose
  • Sorbitol
  • Glycyrrhizic Acid
  • L-Iditol 2-Dehydrogenase
  • Aldehyde Reductase
  • Thiolester Hydrolases
  • hydroxyacylglutathione hydrolase
  • Lactoylglutathione Lyase
  • Glutathione